Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Induced pluripotent stem cells without viral vectors

This article was originally published in Scrip

Executive Summary

The Japanese team which generated induced pluripotent stem (iPS) cells from normal human skin cells last year has developed a new virus-free technique. Professor Shinya Yamanaka and others at Kyoto University successfully transfected mouse embryonic fibroblasts with the requisite genes using plasmids rather than retroviral or lentiviral vectors. These can become integrated into the genome, increasing the risk of cancer. The technique so far has a lower production efficiency and has not been applied to somatic cells. iPS cells behave like embryo-derived stem cells but with none of the ethical and immunogenicity concerns, and may in future be used in novel regenerative therapies.

You may also be interested in...



Japan Enhertu Nod Another Boost For Daiichi's Oncology Hopes

Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.

GTS Alliance Gives Mochida A Cell Therapy Buy-In

Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.

Positive Evidence Stacks Up For Takeda's Dengue Vaccine

New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.

Topics

UsernamePublicRestriction

Register

SC030472

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel